特布他林辅助治疗支原体肺炎患儿的疗效及对CXCL8、P2X7受体的影响

Clinical effect of terbutaline on Mycoplasma pneumonia in children and its impact on CXCL8 and P2X7 receptor levels

目的:探究特布他林对支原体肺炎(MPP)患儿的CXC趋化因子配体8(CXCL8)、P2X7受体的影响。方法:选择2016年6月~2018年5月南通市第二人民医院收治的MPP患儿104例作为研究对象。采用随机数字表法将所选患者分为治疗组和对照组,各52例。常规治疗后对照组给予阿奇霉素序贯疗法治疗,治疗组在此基础上雾化吸入硫酸特布他林。观察两组患儿临床症状消失时间,并测定CXCL8、P2X7受体等的表达,评价临床疗效及不良反应。结果:治疗组患儿临床主要症状、体征消失时间均短于对照组(均P<0.05);治疗组临床治疗效果优于对照组(92.3%vs.76.9%,P<0.05);治疗前两组患儿的CXCL8、P2X7受体及TNF-α和IL-1β表达水平相近(均P>0.05),治疗后各细胞因子水平均降低(P<0.05),与同期对照组比较,治疗组下降幅度更明显(P<0.05);两组用药不良反应发生率比较差异无统计学意义[11.5%(6/52)vs.5.8%(3/52),(P>0.05)]。结论:特布他林辅助治疗MPP患儿可降低CXCL8、P2X7受体表达水平,疗效显著,安全性高。

Objective:To investigate the effect of terbutaline on CXCL8 and P2X7 receptor levels in children of Mycoplasma pneumonia(MPP).Methods:One hundred and four MPP children admitted to Nantong No.2 people′s hospital were included from June 2016 to May 2018,and divided into observational group and control group(n=52 for each group)by random digital table.Children in the control group were treated by conventional regimen plus azithromycin sequential therapy,and those in the observational group were given additional atomized inhalation of terbutaline sulfate on the treatment protocol basis in the control group.Then the two groups were observed and assessed regarding the time of clinical symptom disappearance,expressions of CXCL8 and P2X7 receptors,clinical efficacy and adverse reactions.Results:Children in the observational group had earlier disappearance of primary clinical symptoms and signs than those in the control group(all P<0.05),and had better clinical effect than those in the control group(92.3%vs.76.9%,P<0.05).Expression levels of CXCL8,P2X7 receptor,TNF-αand IL-1β were similar in the two groups before treatment(all P>0.05),yet the levels of all cytokines were significantly decreased following medication(P<0.05),and the decrease was more evident in the observational group(P<0.05).The incidence of adverse drug reactions remained insignificant between the two groups[11.5%(6/52)vs.5.8%(3/52),P>0.05].Conclusion:Terbutalin as adjuvant medication can effectively reduce CXCL8 and P2X7 receptor expression,with higher clinical efficacy and safety.